ClinicalTrials.gg
Drug

Lebrikizumab clinical trials

Also written LY3650150, DRM06 and Ebglyss.

studies test it
48
open now
7
in phase 3
26
first study started
2006

How each study uses lebrikizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lebrikizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Sept 2024 · EBGLYSS · BLA 761306 (FDA, Drugs@FDA)
European Union
16 Nov 2023 · Ebglyss · EMEA/H/C/005894 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lebrikizumab
42
lebrikizumab (MILR1444A)
3

Brand

Ebglyss
3

Development codes

LY3650150
19
DRM06
10
RO5490255
6
TNX-650
1

Studies by the year they started

48 studies that test it; most in 2015 (5)

Studies that test lebrikizumab, by start year
YearStudies
20061
20081
20092
20111
20122
20134
20143
20155
20181
20192
20204
20213
20222
20234
20245
20253
20265

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
14
Phase 3
26
Phase 4
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 44 · Other 4

Eli Lilly and Company (19) · Hoffmann-La Roche (11) · Genentech, Inc. (7) · Almirall, S.A. (6) · Johann E Gudjonsson MD PhD (1) · Forefront Dermatology S.C (1) · University of Maryland, Baltimore (1) · University of California, San Francisco (1)

Often tested with

Tested in the same studies.

Pirfenidone (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 2 in phase 3

Studies that test lebrikizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses lebrikizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 48

See all 48 studies that test lebrikizumab →

As the comparator · 1 — what is tested is compared with lebrikizumab

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call lebrikizumab · ClinicalTrials.gg INT005906

  • MeSH (NLM) C561806lebrikizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) U9JLP7V031LEBRIKIZUMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q3829321lebrikizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C87767LebrikizumabOne source FDA
  • DrugBank DB11914One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.